Provided by Tiger Trade Technology Pte. Ltd.

Merck

143.81
-1.5000-1.03%
Post-market: 143.80-0.0100-0.01%19:59 EDT
Volume:7.86M
Turnover:1.13B
Market Cap:354.80B
PE:112.98
High:145.39
Open:144.71
Low:143.26
Close:145.31
52wk High:156.92
52wk Low:82.01
Shares:2.47B
Float Shares:2.47B
Volume Ratio:0.88
T/O Rate:0.32%
Dividend:3.32
Dividend Rate:2.31%
EPS(TTM):1.27
EPS(LYR):7.28
ROE:6.96%
ROA:11.87%
PB:8.46
PE(LYR):19.75

Loading ...

Citi Remains a Hold on Merck & Company (MRK)

TIPRANKS
·
Sep 29

Merck Starts Phase 1 Trial of Oral Peptide Developed With Cyprumed's Technology

MT Newswires Live
·
Sep 29

Scotiabank Adjusts PT on Merck & Co. to $180 From $155, Keeps Sector Outperform Rating

MT Newswires Live
·
Sep 29

Cyprumed : Eligible to Receive up to $493.00m in Milestones from Merck & Co Collaboration

THOMSON REUTERS
·
Sep 29

US Research Roundup-Acuity, Dell Technologies, Nike

Reuters
·
Sep 29

$20 Billion In Deals And Counting: Lilly's CEO Targets The "White Space" Of Science For Larger M&A

Options & Short Sell
·
Sep 29

Merck & Co Inc : Scotiabank Raises Target Price to $180 from $155

THOMSON REUTERS
·
Sep 29

AstraZeneca To Invest $2 Billion In Summit And Co-Develop Drugs; Shares Jump After Hours

Options & Short Sell
·
Sep 29

Teva Pharmaceutical's Duvakitug Could be Validated by Merck's Tulisokibart Results, Oppenheimer Says

MT Newswires Live
·
Sep 28

US Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 28

Merck in License Pact Worth up to $2.13 Billion with SciBrunch Therapeutics

Dow Jones
·
Sep 28

Merck enters global license agreement with SciBrunch Therapeutics for SPR2015

TIPRANKS
·
Sep 28

Merck Enters into Exclusive Global License Agreement with Scibrunch Therapeutics for Spr2015, an Investigational Oral Kras G12d (On) Inhibitor

Reuters
·
Sep 28

Merck & Co - to Record $400 Mln Pre-Tax Charge, $0.13 Per Share, in Q3 2026

THOMSON REUTERS
·
Sep 28

Merck & Co - Deal Includes $400 Mln Upfront, Total Potential Value $2.13 Bln; Deal Closed

THOMSON REUTERS
·
Sep 28

Merck & Co Inc: Under Agreement, Scibrunch Granted Co Exclusive Rights to Develop, Manufacture & Commercialize Spr2015 Worldwide

THOMSON REUTERS
·
Sep 28

Merck's Keytruda Subcutaneous Formulation Approved for Launch in China

Stock News
·
Sep 28

Ingenia Therapeutics Expects USD 5 Million MK-8748 Milestone Payment from Merck Unit Eyebiotech

Reuters
·
Sep 28

Ifinatamab Deruxtecan Biologics License Application for Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn

Reuters
·
Sep 26

Merck, Daiichi Sankyo Withdraw US Application for Lung Cancer Drug

Reuters
·
Sep 26